Skip to main content
. 2022 Mar 18;17(1):35–40. doi: 10.5114/pg.2022.114595

Table II.

Comparison of patients by AFP concentration

Characteristics AFP < 100 ng/ml
(n = 365)
AFP ≥ 100 ng/ml
(n = 26)
P-value
Gender (M/F) 118/247 6/20 0.327
CEA [U/ml] 2.4 (1–26149) 17 (0.6–56662) < 0.001
CA19-9 [U/ml] 19 (1.2–77924) 25 (1–37849) 0.882
Histopathology: 0.006
Signet-ring cell carcinoma 96 (26.3%) 2 (7.6%)
Poorly differentiated carcinoma 115 (31.5%) 8 (30.7%)
Moderately differentiated carcinoma 70 (19.1%) 2 (7.6%)
Well-differentiated carcinoma 57 (15.6%) 10 (38.4%)
Other 27 (7.3%) 4 (15.3%)
Stage: 0.252
Stage I 28 (7.6%) 0 (0.0%)
Stage II 22 (6.0%) 1 (3.8%)
Stage III 38 (10.4%) 1 (3.8%)
Stage IV 277 (62.1%) 24 (92.3%)
Location of the lesion (proximal/distal) 99/226 7/19 0.982
Metastasis status: < 0.001
Liver metastasis only 84 (23.0%) 18 (69.2%)
Lungs metastasis only 17 (4.6%) 0 (0.0%)
Bone metastasis only 8 (2.1%) 0 (0.0%)
Diffuse metastasis** 120 (32.8%) 3 (11.5%)
No metastasis 136 (37.2%) 5 (19.2%)
Liver metastasis 117 (32.1%) 21 (80.8%) < 0.001

n: Sample size. *Pearson’s χ2 test was used. **Diffuse metastasis: metastasis to ≥ 2 different regions.